{"id":63916,"date":"2022-06-27T18:29:00","date_gmt":"2022-06-27T16:29:00","guid":{"rendered":"https:\/\/blog.cofb.cat\/?p=63916"},"modified":"2023-10-09T14:56:17","modified_gmt":"2023-10-09T14:56:17","slug":"novetats-en-el-tractament-de-la-psoriasi-i-de-lartritis-psoriasica","status":"publish","type":"post","link":"https:\/\/www.cofb.org\/ca\/2022\/06\/27\/novetats-en-el-tractament-de-la-psoriasi-i-de-lartritis-psoriasica\/","title":{"rendered":"Novetats en el tractament de la psoriasi i de l’artritis psori\u00e0sica"},"content":{"rendered":"\n

El passat 2 de juny es va celebrar al Col\u00b7legi de Farmac\u00e8utics de Barcelona<\/strong> la formaci\u00f3 “Novetats en el tractament de la psoriasi i de l’artritis psori\u00e0sica”<\/strong>, organitzada conjuntament amb la Societat Catalana de Farm\u00e0cia Cl\u00ednica<\/a> i que va comptar amb el patrocini de Janssen<\/a>. Els ponents van ser Ramon Jodar,<\/strong> cap del Servei de Farm\u00e0cia de l\u2019Hospital Universitari de Bellvitge, Jordi Mollet<\/strong>, dermat\u00f2leg de l’Hospital Universitari Vall d\u2019Hebron, Alba Erra<\/strong>, reumat\u00f2loga del Servei de Reumatologia i responsable de la l\u00ednia d\u2019artritis psori\u00e0sica de la Unitat d\u2019Inflamaci\u00f3 i Autoimmunitat de l’Hospital Universitari Vall d\u2019Hebron, Montserrat Gin\u00e9s<\/strong>, vicepresidenta primera d\u2019Acci\u00f3 Psoriasi, i Merc\u00e8 Vilanova<\/strong>, pacient i membre de la mateixa associaci\u00f3. David Conde<\/strong>, vocal d’Hospitals del COFB, va introduir la sessi\u00f3.<\/p>\n\n\n\n

\"\"
Ramon Jodar, cap del Servei de Farm\u00e0cia de l\u2019Hospital Universitari de Bellvitge, durant la seva exposici\u00f3.<\/figcaption><\/figure>\n\n\n\n

Adre\u00e7ada a farmac\u00e8utics hospitalaris, els objectius d’aquesta sessi\u00f3 es van centrar en la revisi\u00f3 de les alternatives terap\u00e8utiques <\/strong>en el tractament de l\u2019artritis psori\u00e0sica, con\u00e8ixer les \u00faltimes novetats dels tractaments biol\u00f2gics<\/strong>, entendre l\u2019abordatge compartit del pacient <\/strong>amb psoriasis i artritis psori\u00e0sica, aix\u00ed com debatre sobre l\u2019acc\u00e9s als nous tractaments.<\/strong><\/p>\n\n\n\n

Contribuci\u00f3 dels tractaments biol\u00f2gics<\/strong><\/h2>\n\n\n\n

Va arrencar la formaci\u00f3 amb \u201cInnovaci\u00f3 en els tractaments biol\u00f2gics<\/strong>\u201d, a c\u00e0rrec de Ramon Jodar<\/strong>, cap del Servei de Farm\u00e0cia de l\u2019Hospital Universitari de Bellvitge. Va destacar que la irrupci\u00f3 en terap\u00e8utica de nous biol\u00f2gics \u201cest\u00e0 generant una gran oportunitat de noves estrat\u00e8gies d\u2019abordament d\u2019aquestes malalties<\/strong> immunomediades\u201d com a conseq\u00fc\u00e8ncia de \u201ccon\u00e8ixer millor les noves dianes terap\u00e8utiques\u201d. <\/p>\n\n\n

\n\n\n

L’impacte de l’artritis psori\u00e0sica<\/strong><\/h3>\n\n\n\n

La prevalen\u00e7a de la psoriasi \u00e9s d\u2019aproximadament un 1,4% de la poblaci\u00f3 espanyola<\/strong> i afecta igualment ambd\u00f3s sexes amb pics d\u2019incid\u00e8ncia m\u00e0xima en la segona i en la cinquena d\u00e8cada de la vida. L\u2019artritis psori\u00e0sica es produeix en un 15% de pacients amb psoriasi i pot afectar qualsevol articulaci\u00f3 del cos.<\/strong> L\u2019impacte de l\u2019artritis psori\u00e0sica dep\u00e8n de l\u2019articulaci\u00f3 implicada i de la gravetat dels s\u00edmptomes. Un diagn\u00f2stic preco\u00e7, h\u00e0bits de vida saludables i els tractaments farmacol\u00f2gics idonis milloraran l\u2019estat de salut <\/strong>de les persones que presenten aquestes patologies. <\/p>\n\n\n\n

<\/p> <\/div>\n\n\n\n

En aquest sentit, va precisar que \u201cl\u2019aparici\u00f3 de diferents medicaments amb diverses dianes terap\u00e8utiques i la necess\u00e0ria experi\u00e8ncia d\u2019\u00fas, dibuixen un escenari din\u00e0mic i obert a diferents opcions que s\u2019aniran modulant en els pr\u00f2xims anys\u201d. Respecte al paper dels serveis de farm\u00e0cia <\/strong>els va posar en valor ja que \u201cal tractar-se de malalties cr\u00f2niques, el seu paper \u00e9s molt important en el seguiment dels pacients<\/strong>\u201d. Com a conclusi\u00f3, Jodar va donar-li una gran rellev\u00e0ncia a la irrupci\u00f3 d\u2019aquests tractaments biol\u00f2gics<\/strong> en la ter\u00e0pia, ja que \u201cestan contribuint a millorar espectacularment la vida dels pacients amb psoriasi i artritis psori\u00e0sica<\/strong>\u201d. <\/p>\n\n\n\n

Novetats terap\u00e8utiques en el tractament <\/strong><\/h2>\n\n\n\n

Seguidament, en la seva presentaci\u00f3 sobre les novetats terap\u00e8utiques alternatives en el tractament de l\u2019artritis psori\u00e0sica<\/strong>, Alba Erra<\/strong>, responsable de la l\u00ednia d\u2019artritis psori\u00e0sica de la Unitat d\u2019Inflamaci\u00f3 i Autoimmunitat de l\u2019Hospital Vall d\u2019Hebron, va assenyalar que \u201cla persist\u00e8ncia del tractament en els pacients \u00e9s molt baixa<\/strong>\u201d i que \u201ctot i els tractaments disponibles actualment<\/strong>, hi ha un percentatge de pacients que no en responen<\/strong>\u201d. <\/p>\n\n\n\n

\"Alba
Alba Erra, responsable de la l\u00ednia d\u2019artritis psori\u00e0sica de la Unitat d\u2019Inflamaci\u00f3 i Autoimmunitat de l\u2019Hospital Vall d\u2019Hebron, en un moment de la seva presentaci\u00f3.<\/figcaption><\/figure>\n\n\n\n

En tot cas va destacar que \u201c\u00e9s molt important l\u2019abordatge multidisciplinar de la malaltia<\/strong> a trav\u00e9s de consultes dermatol\u00f2giques i reumatol\u00f2giques\u201d i que la indicaci\u00f3 del tractament ha d\u2019anar cap a \u201cla medicina personalitzada, en funci\u00f3 de la cl\u00ednica i les comorbiditats que presenta el pacient<\/strong> en cada cas\u201d. Aprofundint en els tractaments, Erra va compartir que \u201cl\u2019upadacitinib<\/strong><\/em> ha demostrat efic\u00e0cia<\/strong> als dominis articulars i extraarticulars de l\u2019artritis psori\u00e0sica amb la inhibici\u00f3 selectiva de la JAK-1\u201d. Aix\u00ed mateix,  \u201cel tractament amb guselkumab<\/em> tamb\u00e9 s\u2019ha mostrat efica\u00e7<\/strong> a tots els dominis amb un bon perfil de seguretat\u201d, va concloure. <\/p>\n\n\n\n

Consulta compartida i enfocament integral del pacient<\/strong><\/h2>\n\n\n\n

El dermat\u00f2leg de l’Hospital Vall d’Hebron, Jordi Mollet<\/strong>, va centrar la seva intervenci\u00f3 en l’enfocament integral de pacient amb psoriasi i artritis psori\u00e0sica mitjan\u00e7ant la consulta compartida, des dels \u00e0mbits de la dermatologia i la reumatologia<\/strong>. En primera inst\u00e0ncia, va detallar els avantatges d’una intervenci\u00f3 preco\u00e7 en la patologia, les quals poden anar des de la inhibici\u00f3 o endarreriment de danys estructurals a millores en el dolor, la fatiga, la depressi\u00f3 i la qualitat de vida.<\/p>\n\n\n\n

\"\"
Jordi Mollet, dermat\u00f2leg de l’Hospital Universitari Vall d\u2019Hebron, va abordar la consulta compartida, des dels \u00e0mbits de la dermatologia i la reumatologia.<\/figcaption><\/figure>\n\n\n\n

Mollet va recordar la import\u00e0ncia del dermat\u00f2leg en el cribratge de l’artritis psori\u00e0sica <\/strong>assenyalant que “representa la primera l\u00ednia d’actuaci\u00f3 pel seu diagn\u00f2stic i intervenci\u00f3 i la majoria de pacients veuran a un dermat\u00f2leg abans que apareguin els s\u00edmptomes articulars”, obtenint aix\u00ed “el m\u00e0xim benefici terap\u00e8utic derivant preco\u00e7ment al reumat\u00f2leg per la seva avaluaci\u00f3 i tractament especialitzat<\/strong>“. Aquesta aproximaci\u00f3 col\u00b7laborativa entre reumat\u00f2legs i dermat\u00f2legs “genera tractaments consensuats, satisf\u00e0 als pacients i als professionals, estalvia visites i proves evitant duplicitats, facilita projectes d’investigaci\u00f3 i, sobretot, treballa pel futur de la malaltia psori\u00e0sica<\/strong>“, va concloure el dermat\u00f2leg.<\/p>\n\n\n

\n\n\n

La visi\u00f3 del pacient<\/strong><\/h2>\n\n\n\n

Com a cloenda de la sessi\u00f3, Montserrat Gin\u00e9s<\/strong>, vicepresidenta primera d\u2019Acci\u00f3n Psoriasis, i Merc\u00e8 Vilanova,<\/strong> pacient i membre de la mateixa associaci\u00f3, van abordar l’acc\u00e9s i equitat als nous tractaments. En primer lloc, van recordar que “a cada pacient la malaltia ens afecta d\u2019una manera i en un grau diferent. No nom\u00e9s s\u00f3n les afectacions que es poden tenir a la pell o a les articulacions”<\/strong>. \u201cLa psoriasi i l\u2019artritis psori\u00e0sica tenen una afectaci\u00f3 emocional molt important i forma part de la nostra malaltia<\/strong>\u201d, va assenyalar. A banda de les comorbiditats f\u00edsiques, “la depressi\u00f3 o l\u2019ansietat tamb\u00e9 les patim”. <\/p>\n\n\n\n

\"Montserrat
Montserrat Gin\u00e9s , vicepresidenta primera d\u2019Acci\u00f3n Psoriasis, i Merc\u00e8 Vilanova, pacient i membre de la mateixa associaci\u00f3, van cloure la sessi\u00f3 informativa.<\/figcaption><\/figure>\n\n\n\n

Va recordar la import\u00e0ncia d\u2018associacions com Acci\u00f3n Psoriasis<\/a>, que aquest any compleix 30 anys, i que s\u2019ha convertit en un espai d\u2019acollida per pacients i les seves fam\u00edlies, a la vegada que un espai de formaci\u00f3 per aprendre de la malaltia. Com va destacar Gin\u00e9s, “quan m\u00e9s coneixem de la malaltia millor la podrem portar i millor ser\u00e0 la nostra relaci\u00f3 amb tots els professionals de la salut<\/strong>“.
En l’\u00e0mbit dels tractaments, va recon\u00e8ixer que “els medicaments biol\u00f2gics ens han canviat la vida<\/strong>, per\u00f2 \u00e9s cert que encara estem accedint de manera desigual. Sabem que s\u00f3n tractaments molt cars i de processos complicats”. La vicepresidenta primera d’Acci\u00f3n Psoriasis, va reivindicar que “queda molt per fer, ja que un 47% de pacients amb la malaltia en estadi greu, no est\u00e0 satisfet amb el seu tractament<\/strong>“. <\/p> <\/div>\n\n\n\n

\n
<\/div>\n\n\n\n
<\/div>\n\n\n\n
\n

Activitat organitzada conjuntament amb:<\/strong><\/p>\n\n\n\n

\"\"<\/figure><\/div>\n\n\n\n

Amb el patrocini de:<\/strong><\/p>\n\n\n\n

\"\"<\/figure><\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

El passat 2 de juny es va celebrar al Col\u00b7legi de Farmac\u00e8utics de Barcelona la formaci\u00f3 “Novetats en el tractament de la psoriasi i de l’artritis psori\u00e0sica”, organitzada conjuntament amb la Societat Catalana de Farm\u00e0cia Cl\u00ednica i que va comptar amb el patrocini de Janssen. Els ponents van ser Ramon […]<\/p>\n","protected":false},"author":1,"featured_media":67884,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_uag_custom_page_level_css":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"disabled","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[23,57],"tags":[802,803,209,64,19,79,53,804,231,805,806,807],"class_list":["post-63916","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-destacats","category-mon-collegial","tag-accio-psoriasi","tag-accion-psoriasis","tag-artritis-psoriasica","tag-atencio-farmaceutica","tag-collegi-de-farmaceutics-de-barcelona","tag-dermatologia","tag-farmaceutics","tag-guselkumab","tag-psoriasi","tag-reumatologia","tag-salut-articular","tag-upadacitinib"],"yoast_head":"\nNovetats en el tractament de la psoriasi i de l'artritis psori\u00e0sica - Col\u00b7legi de Farmac\u00e8utics de Barcelona<\/title>\n<meta name=\"description\" content=\"El passat 2 de juny es va celebrar al COFB la formaci\u00f3 "Novetats en el tractament de la psoriasi i de l'artritis psori\u00e0sica"\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/novaorg.cofb.net\/2022\/06\/27\/novetats-en-el-tractament-de-la-psoriasi-i-de-lartritis-psoriasica\/\" \/>\n<meta property=\"og:locale\" content=\"ca_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novetats en el tractament de la psoriasi i de l'artritis psori\u00e0sica - Col\u00b7legi de Farmac\u00e8utics de Barcelona\" \/>\n<meta property=\"og:description\" content=\"El passat 2 de juny es va celebrar al COFB la formaci\u00f3 "Novetats en el tractament de la psoriasi i de l'artritis psori\u00e0sica"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/novaorg.cofb.net\/2022\/06\/27\/novetats-en-el-tractament-de-la-psoriasi-i-de-lartritis-psoriasica\/\" \/>\n<meta property=\"og:site_name\" content=\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/farmaceuticsbcn\/\" \/>\n<meta property=\"article:published_time\" content=\"2022-06-27T16:29:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-10-09T14:56:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/novaorg.cofb.net\/wp-content\/uploads\/2023\/07\/COFB_Novetats-Psoriasi_02062022_1-1024x585-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"585\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"wpAdminCofbOrg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@farmaceuticsbcn\" \/>\n<meta name=\"twitter:site\" content=\"@farmaceuticsbcn\" \/>\n<meta name=\"twitter:label1\" content=\"Escrit per\" \/>\n\t<meta name=\"twitter:data1\" content=\"wpAdminCofbOrg\" \/>\n\t<meta name=\"twitter:label2\" content=\"Temps estimat de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minuts\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/novaorg.cofb.net\/2022\/06\/27\/novetats-en-el-tractament-de-la-psoriasi-i-de-lartritis-psoriasica\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2022\/06\/27\/novetats-en-el-tractament-de-la-psoriasi-i-de-lartritis-psoriasica\/\"},\"author\":{\"name\":\"wpAdminCofbOrg\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb\"},\"headline\":\"Novetats en el tractament de la psoriasi i de l’artritis psori\u00e0sica\",\"datePublished\":\"2022-06-27T16:29:00+00:00\",\"dateModified\":\"2023-10-09T14:56:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2022\/06\/27\/novetats-en-el-tractament-de-la-psoriasi-i-de-lartritis-psoriasica\/\"},\"wordCount\":1279,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.cofb.org\/#organization\"},\"image\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2022\/06\/27\/novetats-en-el-tractament-de-la-psoriasi-i-de-lartritis-psoriasica\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/07\/COFB_Novetats-Psoriasi_02062022_1-1024x585-1.jpg\",\"keywords\":[\"Acci\u00f3 Psoriasi\",\"Acci\u00f3n Psoriasis\",\"artritis psori\u00e0sica\",\"Atenci\u00f3 farmac\u00e8utica\",\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"dermatologia\",\"farmac\u00e8utics\",\"guselkumab\",\"psoriasi\",\"reumatologia\",\"salut articular\",\"upadacitinib\"],\"articleSection\":[\"Destacats\",\"M\u00f3n col\u00b7legial\"],\"inLanguage\":\"ca\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/novaorg.cofb.net\/2022\/06\/27\/novetats-en-el-tractament-de-la-psoriasi-i-de-lartritis-psoriasica\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/novaorg.cofb.net\/2022\/06\/27\/novetats-en-el-tractament-de-la-psoriasi-i-de-lartritis-psoriasica\/\",\"url\":\"https:\/\/novaorg.cofb.net\/2022\/06\/27\/novetats-en-el-tractament-de-la-psoriasi-i-de-lartritis-psoriasica\/\",\"name\":\"Novetats en el tractament de la psoriasi i de l'artritis psori\u00e0sica - Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"isPartOf\":{\"@id\":\"https:\/\/www.cofb.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2022\/06\/27\/novetats-en-el-tractament-de-la-psoriasi-i-de-lartritis-psoriasica\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2022\/06\/27\/novetats-en-el-tractament-de-la-psoriasi-i-de-lartritis-psoriasica\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/07\/COFB_Novetats-Psoriasi_02062022_1-1024x585-1.jpg\",\"datePublished\":\"2022-06-27T16:29:00+00:00\",\"dateModified\":\"2023-10-09T14:56:17+00:00\",\"description\":\"El passat 2 de juny es va celebrar al COFB la formaci\u00f3 \\\"Novetats en el tractament de la psoriasi i de l'artritis psori\u00e0sica\\\"\",\"breadcrumb\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2022\/06\/27\/novetats-en-el-tractament-de-la-psoriasi-i-de-lartritis-psoriasica\/#breadcrumb\"},\"inLanguage\":\"ca\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/novaorg.cofb.net\/2022\/06\/27\/novetats-en-el-tractament-de-la-psoriasi-i-de-lartritis-psoriasica\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/novaorg.cofb.net\/2022\/06\/27\/novetats-en-el-tractament-de-la-psoriasi-i-de-lartritis-psoriasica\/#primaryimage\",\"url\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/07\/COFB_Novetats-Psoriasi_02062022_1-1024x585-1.jpg\",\"contentUrl\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/07\/COFB_Novetats-Psoriasi_02062022_1-1024x585-1.jpg\",\"width\":1024,\"height\":585},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/novaorg.cofb.net\/2022\/06\/27\/novetats-en-el-tractament-de-la-psoriasi-i-de-lartritis-psoriasica\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Inici\",\"item\":\"https:\/\/novaorg.cofb.net\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novetats en el tractament de la psoriasi i de l’artritis psori\u00e0sica\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.cofb.org\/#website\",\"url\":\"https:\/\/www.cofb.org\/\",\"name\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.cofb.org\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.cofb.org\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"ca\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.cofb.org\/#organization\",\"name\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"url\":\"https:\/\/www.cofb.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png\",\"contentUrl\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png\",\"width\":500,\"height\":105,\"caption\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\"},\"image\":{\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/farmaceuticsbcn\/\",\"https:\/\/twitter.com\/farmaceuticsbcn\",\"https:\/\/www.instagram.com\/farmaceuticsbcn\/\",\"https:\/\/www.linkedin.com\/company\/farmaceuticsbcn\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb\",\"name\":\"wpAdminCofbOrg\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g\",\"caption\":\"wpAdminCofbOrg\"},\"sameAs\":[\"http:\/\/192.168.64.122\/wordpress\"],\"url\":\"https:\/\/www.cofb.org\/ca\/author\/wpadmincofborg\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Novetats en el tractament de la psoriasi i de l'artritis psori\u00e0sica - Col\u00b7legi de Farmac\u00e8utics de Barcelona","description":"El passat 2 de juny es va celebrar al COFB la formaci\u00f3 \"Novetats en el tractament de la psoriasi i de l'artritis psori\u00e0sica\"","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/novaorg.cofb.net\/2022\/06\/27\/novetats-en-el-tractament-de-la-psoriasi-i-de-lartritis-psoriasica\/","og_locale":"ca_ES","og_type":"article","og_title":"Novetats en el tractament de la psoriasi i de l'artritis psori\u00e0sica - Col\u00b7legi de Farmac\u00e8utics de Barcelona","og_description":"El passat 2 de juny es va celebrar al COFB la formaci\u00f3 \"Novetats en el tractament de la psoriasi i de l'artritis psori\u00e0sica\"","og_url":"https:\/\/novaorg.cofb.net\/2022\/06\/27\/novetats-en-el-tractament-de-la-psoriasi-i-de-lartritis-psoriasica\/","og_site_name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","article_publisher":"https:\/\/www.facebook.com\/farmaceuticsbcn\/","article_published_time":"2022-06-27T16:29:00+00:00","article_modified_time":"2023-10-09T14:56:17+00:00","og_image":[{"width":1024,"height":585,"url":"https:\/\/novaorg.cofb.net\/wp-content\/uploads\/2023\/07\/COFB_Novetats-Psoriasi_02062022_1-1024x585-1.jpg","type":"image\/jpeg"}],"author":"wpAdminCofbOrg","twitter_card":"summary_large_image","twitter_creator":"@farmaceuticsbcn","twitter_site":"@farmaceuticsbcn","twitter_misc":{"Escrit per":"wpAdminCofbOrg","Temps estimat de lectura":"7 minuts"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/novaorg.cofb.net\/2022\/06\/27\/novetats-en-el-tractament-de-la-psoriasi-i-de-lartritis-psoriasica\/#article","isPartOf":{"@id":"https:\/\/novaorg.cofb.net\/2022\/06\/27\/novetats-en-el-tractament-de-la-psoriasi-i-de-lartritis-psoriasica\/"},"author":{"name":"wpAdminCofbOrg","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb"},"headline":"Novetats en el tractament de la psoriasi i de l’artritis psori\u00e0sica","datePublished":"2022-06-27T16:29:00+00:00","dateModified":"2023-10-09T14:56:17+00:00","mainEntityOfPage":{"@id":"https:\/\/novaorg.cofb.net\/2022\/06\/27\/novetats-en-el-tractament-de-la-psoriasi-i-de-lartritis-psoriasica\/"},"wordCount":1279,"commentCount":0,"publisher":{"@id":"https:\/\/www.cofb.org\/#organization"},"image":{"@id":"https:\/\/novaorg.cofb.net\/2022\/06\/27\/novetats-en-el-tractament-de-la-psoriasi-i-de-lartritis-psoriasica\/#primaryimage"},"thumbnailUrl":"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/07\/COFB_Novetats-Psoriasi_02062022_1-1024x585-1.jpg","keywords":["Acci\u00f3 Psoriasi","Acci\u00f3n Psoriasis","artritis psori\u00e0sica","Atenci\u00f3 farmac\u00e8utica","Col\u00b7legi de Farmac\u00e8utics de Barcelona","dermatologia","farmac\u00e8utics","guselkumab","psoriasi","reumatologia","salut articular","upadacitinib"],"articleSection":["Destacats","M\u00f3n col\u00b7legial"],"inLanguage":"ca","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/novaorg.cofb.net\/2022\/06\/27\/novetats-en-el-tractament-de-la-psoriasi-i-de-lartritis-psoriasica\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/novaorg.cofb.net\/2022\/06\/27\/novetats-en-el-tractament-de-la-psoriasi-i-de-lartritis-psoriasica\/","url":"https:\/\/novaorg.cofb.net\/2022\/06\/27\/novetats-en-el-tractament-de-la-psoriasi-i-de-lartritis-psoriasica\/","name":"Novetats en el tractament de la psoriasi i de l'artritis psori\u00e0sica - Col\u00b7legi de Farmac\u00e8utics de Barcelona","isPartOf":{"@id":"https:\/\/www.cofb.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/novaorg.cofb.net\/2022\/06\/27\/novetats-en-el-tractament-de-la-psoriasi-i-de-lartritis-psoriasica\/#primaryimage"},"image":{"@id":"https:\/\/novaorg.cofb.net\/2022\/06\/27\/novetats-en-el-tractament-de-la-psoriasi-i-de-lartritis-psoriasica\/#primaryimage"},"thumbnailUrl":"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/07\/COFB_Novetats-Psoriasi_02062022_1-1024x585-1.jpg","datePublished":"2022-06-27T16:29:00+00:00","dateModified":"2023-10-09T14:56:17+00:00","description":"El passat 2 de juny es va celebrar al COFB la formaci\u00f3 \"Novetats en el tractament de la psoriasi i de l'artritis psori\u00e0sica\"","breadcrumb":{"@id":"https:\/\/novaorg.cofb.net\/2022\/06\/27\/novetats-en-el-tractament-de-la-psoriasi-i-de-lartritis-psoriasica\/#breadcrumb"},"inLanguage":"ca","potentialAction":[{"@type":"ReadAction","target":["https:\/\/novaorg.cofb.net\/2022\/06\/27\/novetats-en-el-tractament-de-la-psoriasi-i-de-lartritis-psoriasica\/"]}]},{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/novaorg.cofb.net\/2022\/06\/27\/novetats-en-el-tractament-de-la-psoriasi-i-de-lartritis-psoriasica\/#primaryimage","url":"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/07\/COFB_Novetats-Psoriasi_02062022_1-1024x585-1.jpg","contentUrl":"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/07\/COFB_Novetats-Psoriasi_02062022_1-1024x585-1.jpg","width":1024,"height":585},{"@type":"BreadcrumbList","@id":"https:\/\/novaorg.cofb.net\/2022\/06\/27\/novetats-en-el-tractament-de-la-psoriasi-i-de-lartritis-psoriasica\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Inici","item":"https:\/\/novaorg.cofb.net\/"},{"@type":"ListItem","position":2,"name":"Novetats en el tractament de la psoriasi i de l’artritis psori\u00e0sica"}]},{"@type":"WebSite","@id":"https:\/\/www.cofb.org\/#website","url":"https:\/\/www.cofb.org\/","name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","description":"","publisher":{"@id":"https:\/\/www.cofb.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cofb.org\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"ca"},{"@type":"Organization","@id":"https:\/\/www.cofb.org\/#organization","name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","url":"https:\/\/www.cofb.org\/","logo":{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/","url":"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png","contentUrl":"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png","width":500,"height":105,"caption":"Col\u00b7legi de Farmac\u00e8utics de Barcelona"},"image":{"@id":"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/farmaceuticsbcn\/","https:\/\/twitter.com\/farmaceuticsbcn","https:\/\/www.instagram.com\/farmaceuticsbcn\/","https:\/\/www.linkedin.com\/company\/farmaceuticsbcn\/"]},{"@type":"Person","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb","name":"wpAdminCofbOrg","image":{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g","caption":"wpAdminCofbOrg"},"sameAs":["http:\/\/192.168.64.122\/wordpress"],"url":"https:\/\/www.cofb.org\/ca\/author\/wpadmincofborg\/"}]}},"uagb_featured_image_src":{"full":["https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/07\/COFB_Novetats-Psoriasi_02062022_1-1024x585-1.jpg",1024,585,false],"thumbnail":["https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/07\/COFB_Novetats-Psoriasi_02062022_1-1024x585-1-150x150.jpg",150,150,true],"medium":["https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/07\/COFB_Novetats-Psoriasi_02062022_1-1024x585-1-300x171.jpg",300,171,true],"medium_large":["https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/07\/COFB_Novetats-Psoriasi_02062022_1-1024x585-1-768x439.jpg",768,439,true],"large":["https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/07\/COFB_Novetats-Psoriasi_02062022_1-1024x585-1.jpg",1024,585,false],"1536x1536":["https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/07\/COFB_Novetats-Psoriasi_02062022_1-1024x585-1.jpg",1024,585,false],"2048x2048":["https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/07\/COFB_Novetats-Psoriasi_02062022_1-1024x585-1.jpg",1024,585,false],"trp-custom-language-flag":["https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/07\/COFB_Novetats-Psoriasi_02062022_1-1024x585-1.jpg",18,10,false]},"uagb_author_info":{"display_name":"wpAdminCofbOrg","author_link":"https:\/\/www.cofb.org\/ca\/author\/wpadmincofborg\/"},"uagb_comment_info":0,"uagb_excerpt":"El passat 2 de juny es va celebrar al Col\u00b7legi de Farmac\u00e8utics de Barcelona la formaci\u00f3 “Novetats en el tractament de la psoriasi i de l’artritis psori\u00e0sica”, organitzada conjuntament amb la Societat Catalana de Farm\u00e0cia Cl\u00ednica i que va comptar amb el patrocini de Janssen. Els ponents van ser Ramon […]","_links":{"self":[{"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/posts\/63916","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/comments?post=63916"}],"version-history":[{"count":5,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/posts\/63916\/revisions"}],"predecessor-version":[{"id":69018,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/posts\/63916\/revisions\/69018"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/media\/67884"}],"wp:attachment":[{"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/media?parent=63916"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/categories?post=63916"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/tags?post=63916"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}